• 1
    Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, Reid EM, Rhodes J 1987 Osteoporosis in patients with inflammatory bowel disease. Gut 28: 410415.
  • 2
    Lichtenstein GR 2003 Evaluation of bone mineral density in inflammatory bowel disease: Current safety focus. Am J Gastroenterol 98: S24S30.
  • 3
    Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SMPF 1998 Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 42: 188194.
  • 4
    Vogelsang H, Ferenci P, Woloszczuk W, Resch H, Herold C, Frotz S, Gangl A 1989 Bone disease in vitamin D-deficient patients with Crohn's disease. Dig Dis Sci 34: 10941099.
  • 5
    Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F 1995 Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 10: 250256.
  • 6
    Ghosh S, Cowen S, Hannan WJ, Ferguson A 1994 Low bone mineral density in Crohns' disease, but not ulcerative colitis, at diagnosis. Gastroenterology 107: 10311039.
  • 7
    Lamb EJ, Wong T, Smith DJ, Simpson DE, Coakley AJ, Moniz C, Muller AF 2002 Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 16: 18951902.
  • 8
    Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C 1997 Reduced bone density in patients with inflammatory bowel disease. Gut 40: 228233.
  • 9
    Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, Passariello R, Cucchiara S 2007 Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis 13: 416423.
  • 10
    De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, Vivarelli M, Muratori F, Berni S, Ballanti P, Ferrari S, Teti A 2006 Impaired skeletal development in interleukin-6-transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 54: 35513563.
  • 11
    Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y 2004 IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15: 4960.
  • 12
    Ragab AA, Nalepka JL, Bi Y, Greenfield EM 2002 Cytokines synergistically induce osteoclast differentiation: Support by immortalized or normal calvarial cells. Am J Physiol Cell Physiol 283: C679C687.
  • 13
    Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H 2005 The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 54: 479487.
  • 14
    Compston J 2003 Osteoporosis in inflammatory bowel disease. Gut 52: 6364.
  • 15
    van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK 2003 Inflammatory bowel disease and the risk of fracture. Gastroenterology 125: 15911597.
  • 16
    Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow M, Latham J 2003 Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 62676276.
  • 17
    Hamersma H, Gardner J, Beighton P 2003 The natural history of sclerosteosis. Clin Genet 63: 192197.
  • 18
    Balemans W, Ebeling M, Patel N, Van Hul E, Olsen P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W 2001 Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537543.
  • 19
    Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersama H, Beighton P, Mulligan J 2001 Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine-knot containing protein. Am J Hum Genet 68: 577589.
  • 20
    Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D 2005 Sclerostin binds to LRP5/6 and antagonises canonical Wnt signalling. J Biol Chem 280: 1988319887.
  • 21
    Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R 2006 Bone density ligand Sclerostin directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 21: 17381749.
  • 22
    Semenov MV, He X 2006 LRP5 mutations linked to hight bone mass diseases cause reduced binding and inhibition by SOST. J Biol Chem 281: 3827638284.
  • 23
    Baron R, Rawadi G, Roman-Roman S 2006 Wnt signalling a: A key regulator of bone mass. Curr Top Dev Biol 76: 103127.
  • 24
    Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Rollinson S, Lippet JM, Child JA, Dunstan C, Felsburg PJ, Morgan GJ, Carding SR 2003 Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19: 849861.
  • 25
    Dresner-Pollak R, Gelb N, Rachmilewitz D, Karmeli F, Weinreb M 2004 Interleukin 10-deficient mice develop osteopenia, decreased bone formation, and mechanical fragility of long bones. Gastroenterology 127: 792801.
  • 26
    Byrne FR, Morony S, Warmington K, Geng Z, Brown HL, Flores SA, Fiorino M, Yin SL, Hill D, Porkess V, Duryea D, Pretorius JK, Adamu S, Manoukian R, Danilenko DM, Sarosi I, Lacey DL, Kostenuik PJ, Senaldi G 2005 CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 54: 7886.
  • 27
    Babcook JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW 1996 A novel Strategy for generating monoclonal antibodies from single lymphocytes producing antibodies of defined specificity. Proc Natl Acad Sci USA 93: 78437848.
  • 28
    Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD 2009 Characterisation of the structural features and interactions of sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284: 1089010900.
  • 29
    Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL 1993 Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C.B-17 SCID mice. Int Immunol 5: 14611471.
  • 30
    Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F 2003 CD4+CD25+ TR cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 197: 111119.
  • 31
    Tilg H, Kaser A, Pines A, Dotan I 2008 Gut, inflammation and osteoporosis: Basic and clinical concepts. Gut 57: 684694.
  • 32
    Guo R, Yamashita M, Zhang Q, Zhou Q, Chen D, Reynolds DG, Awad HA, Yanoso L, Zhao L, Schwarz EM, Zhang YE, Boyce BF, Xing L 2008 Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteosomal degradation of bone morphogenic signalling proteins. J Biol Chem 283: 2308423092.
  • 33
    Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C 2008 Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23: 860869.
  • 34
    Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu Q-T, Ke HK, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C 2009 Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578588.
  • 35
    Ominsky M, Stouch B, Doellgast G, Gong J, Cao J, Gao Y, Tipton B, Haldankar R, Winters A, Ho S, Chen Q, Graham K, Hara S, Deshpande R, Zhou L, Hale M, Henry A, Stephens P, Lawson A, Lightwood D, Perkins V, Kirby H, Moore A, Popplewell A, Robinson M, Vlasseros F, Jolette J, Smith SY, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C 2006 Administration of sclerostin monoclonal antibodies to female cynomolgus monkeys results in increased bone formation, bone mineral density and bone strength. J Bone Miner Res 21: S1: S44.
  • 36
    Padhi D, Stouch B, Jang G, Fang L, Darling M, Glise H, Robinson M, Harris S, Posvar E 2007 Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res 22: S1; S37.
  • 37
    Warmington K, Ominsky M, Bolon B, Cattley R, Stephens P, Lawson A, Lightwood D, Perkins V, Kirby H, Moore A, Robinson M, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C 2005 Sclerostin monoclonal antibody treatment of osteoporotic rats completely reverses one year of ovariectomy-induced systemic bone loss. J Bone Miner Res 20: S1; S22.
  • 38
    Bennett CN, Ouyang H, Ma YL, Zeng Q, Gerin I, Sousa KM, Lane TF, Krishnan V, Hankenson KD, MacDougald OA 2007 Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res 22: 19241932.
  • 39
    Kim JB, Leucht P, Lam K, Luppen C, Ten Berge D, Nusse R, Helms JA 2007 Bone regeneration is regulated by Wnt signalling. J Bone Miner Res 22: 19131923.
  • 40
    Holmem SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO 2005 Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 280: 2116221168.
  • 41
    Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG 2006 Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 119: 12831296.